Saturday, 22 July 2017

Gilead's cancer drug under FDA scrutiny

15 March 2016 | Regulatory | By BioSpectrum Bureau

Gilead's cancer drug under FDA scrutiny

Zydelig is currently approved by the FDA for the treatment of relapsed chronic lymphocytic leukemia

Zydelig is currently approved by the FDA for the treatment of relapsed chronic lymphocytic leukemia

Singapore: US Food and Drug Administration has raised alarm for Gilead Science's cancer medicine Zydelig (idelalisib) due to incoming reports of an increased rate of adverse events, including deaths.

According to FDA, Gilead Sciences has decided to halt six clinical trials in patients with chronic lymphocytic leukemia, small lymphocytic lymphoma and indolent non-Hodgkin lymphomas.

Zydelig is currently approved by the FDA for the treatment of relapsed chronic lymphocytic leukemia, in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities; relapsed follicular B-cell non-Hodgkin lymphoma in patients who have received at least two prior systemic therapies; relapsed small lymphocytic lymphoma in patients who have received at least two prior systemic therapies.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

Survey Box

Is value- based patient healthcare system more effective in Asian countries?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls